


What is claimed:

1. A compound of the general Formula I:



wherein:

R¹ is selected from H and C₂-C₆-acyl;

R², R³, R⁴ and R⁵ are independently selected from H and C₁-C₆-alkyl and at least one among R², R³, R⁴ and R⁵ is C₁-C₆-alkyl;

R⁶ is selected from OH and NR⁷R⁸ wherein R⁷ and R⁸ are independently selected from H and C₁-C₆-alkyl; and salts and tritiated derivatives thereof.

2. A compound according to claim 1, wherein R¹ is C₂-C₆-acyl.

3. A compound according to claim 1, wherein R¹ is selected from formyl, acetyl, propionoyl and butyryl.

4. A compound according to claim 1, wherein R¹ is acetyl.

5. A compound according to claim 1, wherein the stereochemistry at all the α -carbon atoms is L;

6. A compound according to claims 1 to 5, wherein R⁶ is NR⁷R⁸ wherein R⁷ and R⁸ are independently selected from H and C₁-C₆-alkyl and the stereochemistry at all the α -carbon atoms is L.

7. A compound according to any one of the preceding claims, wherein R⁶ is NH₂.

5 8. A compound according to any one of the preceding claims wherein R² is H; R⁴ and R⁵ are independently selected from H and methyl.

9. A compound according to any one of the preceding claims, wherein R³ is methyl.

10 10. A compound according to claim 9, wherein R², R⁴ and R⁵ are H.

11. A compound of claim 9 wherein R⁴ and R⁵ are methyl; R² is H.

15 12. A compound of claim 9 wherein R⁵ is methyl; R² and R⁴ are H.

13. A compound of claim 9 wherein R⁴ is methyl; R² and R⁵ is H.

14. A compound according to any one of the preceding claims selected from the
20 following group:

Ac-Leu-Pro-N(Me)-Phe-Phe-Asp-NH₂

Ac-Leu-Pro-Phe-N(Me)-Phe-Asp-NH₂

25 Ac-Leu-Pro-Phe-N(Me)-Phe-N(Me)-Asp-NH₂

Ac-Leu-Pro-N(Me)-Phe-Phe-N(Me)-Asp-NH₂

30 Ac-Leu-Pro-N(Me)-Phe-N(Me)-Phe-Asp-NH₂

Ac-Leu-Pro-N(Me)-Phe-N(Me)-Phe-N(Me)-Asp-NH₂

Ac-Leu-[³H]Pro-N(Me)-Phe-Phe-Asp-NH₂

15. A compound according to any one of the preceding claims for use as a medicament.

5

16. A pharmaceutical composition comprising a compound according to any one of claims 1 to 14, and a pharmaceutically acceptable excipient, diluent or carrier.

10 17. Use of a compound according to any one of claims 1 to 14 for the manufacture of a medicament for the treatment or prevention of a disease or condition selected from Alzheimer's disease, Dementia pugilistica (including head trauma), Hereditary Cerebral Haemorrhage with amyloidosis of the Dutch type (HCHWA-D) and vascular dementia with amyloid angiopathy.

15

18. Use according to claim 17, wherein the disease is Alzheimer's disease.

19. Use of a compound according to any one of claims 1 to 14, for the preparation of a medicament for the treatment of a disease associated with abnormal protein folding into amyloid and amyloid-like deposits.